Choice Institutional Equities has identified Park Medi World as a key beneficiary of the ongoing rotation into Indian healthcare stocks, projecting a 20% upside for the hospital operator.
The brokerage maintains a buy recommendation, underpinned by a forecast that sees the company’s revenue more than double over the next three years.
5%, suggesting the operator can scale without significant margin compression.
The firm expects Park Medi World’s revenue to rise from ₹16.8 billion in fiscal 2026 to ₹39.4 billion by fiscal 2029.
This growth trajectory is supported by an assumption of stable EBITDA margins at 26.5%, suggesting the operator can scale without significant margin compression.
The update comes as broader market sentiment shifts away from technology-heavy portfolios toward defensive healthcare plays.
Indian healthcare equities have emerged as one of the market’s stronger performers recently, with pharmaceutical and biotech names attracting renewed investor interest.